Mental Health, Mental Illness & Addiction : CMA Submission to the Standing Committee on Social affairs, Science and Technology
https://policybase.cma.ca/link/policy1950

POLICY TYPE  Parliamentary submission
LAST REVIEWED  2012-03-03
DATE  2005-04-20
TOPICS  Population health, health equity, public health
         Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Cannabis for Medical Purposes

Cannabis use and seniors (Update 2017)

CMA Policybase - Canadian Medical Association
MEDICATION USE AND SENIORS (UPDATE 2017)

Data Canadian survey by the long-term care sector of their expectations and use the top-10
medications in terms of frequency of use, the following medications were identified as the most
commonly used by seniors: nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, antihyperten-
sive agents, and oral antidiabetic agents. The top-10 medicinal agents prescribed for seniors in
Canada are:
- Benzenesulfonyl fluoride (NSAID)
- Colchicine
- Calcium channel blockers
- Antihypertensive agents
- Antidiabetic agents
- Antidepressants
- Antihistamines
- Antiplatelet agents
- Opioids
- Anticonvulsants

The Canadian Medical Association (CMA) supports the development of a national
framework for the management of pain and drug use in seniors. This framework should be
developed based on evidence-based guidelines and best practices, and may be tailored to
specific regions or settings.

CMA's Submission to the House of Commons Standing Committee on Health:
CMA Policybase - Canadian Medical Association
CMA’s Submission to the House of Commons Standing Committee on Health: Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE
Parliamentary submission

DATE
2012-03-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology – Prescription Drugs: Clinical Trials and Approval
https://policybase.cma.ca/link/policy10437

POLICY TYPE
Parliamentary submission

DATE
2012-05-09

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE  Parliamentary submission
DATE  2012-10-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada
https://policybase.cma.ca/link/policy10756

POLICY TYPE  Policy document
LAST REVIEWED  2017-03-04
DATE  2013-05-25
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE
Parliamentary submission

DATE
2013-11-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations
https://policybase.cma.ca/link/policy11114

POLICY TYPE                  Response to consultation
DATE                       2014-03-17
TOPICS                      Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE  Parliamentary submission
DATE  2014-03-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase

https://policybase.cma.ca/link/policy11129

POLICY TYPE  Parliamentary submission
DATE  2014-05-15
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Health risks and harms associated with the use of marijuana

https://policybase.cma.ca/link/policy11138

POLICY TYPE  Parliamentary submission
DATE  2014-05-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE  
Response to consultation

DATE  
2014-07-11

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE  Response to consultation
DATE  2014-08-26
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE                               Parliamentary submission
DATE                                    2014-10-28
TOPICS                           Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11519

POLICY TYPE Parliamentary submission
DATE 2015-05-14
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents